fbpx
Medical Innovation Exchange

OBI Pharma culls early cancer asset as it focuses on later-stage bets

https://www.fiercebiotech.com/biotech/keeping-cancer-costs-down-taiwans-obi-pharma-drops-antibody-over-early-stage-trial-results

Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.